ImmunoGen to raise $67 million
This article was originally published in Scrip
ImmunoGen Ghas priced its public offering, from which it expects to receive net proceeds of about $67.4 million. The firm has not broken down how or when it expects to spend the cash, and says its board of directors retains broad discretion over its allocation. In the meantime it will be invested in short-term, investment-grade, interest-bearing securities.